NDA 17322, held by Pharmalucence. Selenomethionine Se-75.
As of Nov 14, 2026, NDA 17322 (Selenomethionine Se 75), held by Pharmalucence, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Selenomethionine Se 75500uCi/ML ยท injectable;injection | Selenomethionine Se-75 | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
